MediWound Reports Q1 Revenue Miss, Increased Losses, and Delays in Key Clinical Trial and Manufacturing

summarizeSummary

MediWound reported Q1 revenue significantly below analyst estimates and increased losses, coupled with high cash burn and delays in its key EscharEx clinical trial and NexoBrid manufacturing capacity.

check_boxKey Events

• Q1 2026 Financial Results Miss

  Revenue for Q1 2026 was $1.5 million, significantly missing analyst expectations of $3.117 million. Net loss increased to $3.0 million ($0.23 per share) compared to $0.7 million ($0.07 per share) in Q1 2025, despite an EPS beat against analyst estimates of -$0.65.

• Significant Cash Burn

  The company reported $9.6 million in net cash used in operating activities during Q1 2026, reducing cash, cash equivalents, and deposits to $45 million as of March 31, 2026, from $54 million at year-end 2025.

• EscharEx Phase III Trial Delayed

  Enrollment in the global Phase III VALUE study for EscharEx in venous leg ulcers is progressing slower than anticipated, with interim assessment and enrollment completion now expected by the end of Q1 2027.

• NexoBrid Manufacturing Capacity Delayed

  Commercial supply from the expanded NexoBrid manufacturing facility is subject to regulatory approval, with recommended modifications identified by the European Medicines Agency (EMA) expected to be implemented during the second half of 2026.

auto_awesomeAnalysis

MediWound's first-quarter results show a significant revenue miss compared to analyst expectations and increased net losses, alongside a substantial cash burn. Critically, the company announced delays in its pivotal EscharEx Phase III trial and the regulatory approval for expanded NexoBrid manufacturing capacity. While the full-year revenue guidance was reaffirmed, these operational setbacks and financial underperformance raise concerns about the company's near-term execution and cash runway, despite an EPS beat and the previously announced BARDA contract.